odronextamab
regeneron
['odronextamab', 'dlbcl', 'lymsm', 'elm-2']
congress |#17icml| michelle poon reports data from the phase ii elm-2 study on odronextamab in heavily pre-treated pts with r/r dlbcl. it showed clinically meaningful efficacy, durable crs &amp; a manageable safety profile.
-orr was 49.2%, with cr of 30.8%
-mostly grade 1 crs
#lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm